LightOx Ltd, a company developing novel therapeutic treatments including light activated chemotherapy for early-stage oral cancer, has appointed Rebecca Crow as Head of Projects.
The new appointment takes the life sciences business to a team of 11 as they move into larger offices at their city centre base in Newcastle. Rebecca’s appointment supports their goal of bringing their revolutionary mouth cancer treatment to market.
Joining in January 2024 as Head of Projects and following a wave of new investment, project launches and grant funding, Rebecca will be responsible for helping the business deliver on a number of their targets. Working with key partners, the appointment aims to prepare the business for the launch of clinical trials for the lead candidate LXD191 to treat mouth cancer.
Dr Sam Whitehouse, Chief Executive Officer at LightOx said: “I am delighted to welcome Rebecca to the team. She brings with her a real wealth of experience with former roles in the Newcastle Gateshead investment team and at the Newcastle NHS Trust where she was responsible for managing a number of trials. Her knowledge will be invaluable in helping us navigate our own way towards clinic and we have every confidence that Rebecca will play a huge part in helping us achieve just that.”
Rebecca Crow, Head of Projects at LightOx said: “I am delighted to join the LightOx team and to have the opportunity to play a role in bringing this revolutionary mouth cancer drug to market. I’ve always admired the work of the team and their goal to develop the first minimally invasive mouth cancer treatment. They have made great progress with increasing interest from investors and stakeholders, and I look forward to supporting them on their journey.”